A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.
The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.
Results of the study will be presented Dec. 9 at the 54th Annual Meeting of the American Society of Hematology.
"Graft-vs.-host disease is the most serious complication from transplant that limits our ability to offer it more broadly. Current prevention strategies have remained mostly unchanged over the past 20 years. This study has us cautiously excited that there may be a potential new way to prevent this condition," says lead study author Sung Choi, M.D., assistant professor of pediatrics at the U-M Medical School.
Vorinostat is currently approved by the U.S. Food and Drug Administration to treat certain types of cancer. But U-M researchers, led by senior study author Pavan Reddy, M.D., found in laboratory studies that the drug had anti-inflammatory effects as well – which they hypothesized could be useful in preventing graft-vs.-host disease, a condition in which the new donor cells begin attacking other cells in the patient's body.
Choi will present data on the first 47 patients enrolled on the study at the University of Michigan Comprehensive Cancer Center and Washington University. Participants were older adults who were undergoing a reduced-intensity bone marrow transplant with cells donated from a relative. Patients received standard medication used after a transplant to prevent graft-vs.-host disease. They also received vorinostat, which is given as a pill taken orally.
The researchers found vorinostat was safe and tolerable to give to this vulnerable population, with manageable side effects. In addition, rates of patient death and cancer relapse among the study participants were similar to historical averages.
The results mirror those found in the laboratory using mice. Reddy, an associate professor of internal medicine at the U-M Medical School, has been studying this approach in the lab for eight years.
"This is an entirely new approach to preventing graft-vs.-host disease," Choi says. Specifically, vorinostat targets histone deacetylases, which are different from the usual molecules targeted by traditional treatments.
"Vorinostat has a dual effect as an anti-cancer and an anti-inflammatory agent. That's what's potentially great about using it to prevent graft-vs.-host, because it may also help prevent the leukemia from returning," Choi says.
The study is continuing to enroll participants. The researchers hope next to test vorinostat in patients receiving a transplant from an unrelated donor, which carries an even greater risk of graft-vs.-host disease. This approach is not currently available outside of this clinical trial.
Note for patients: If you would like more information about the current clinical trial or about other treatment options at the University of Michigan Comprehensive Cancer Center, call the Cancer AnswerLine at 800-865-1125.
From U-M: Thomas M. Braun, Ph.D.; Guoqing Hou, Ph.D.; John E. Levine, M.D., M.S.; Yaping Sun, M.D., Ph.D.; Daniel R. Couriel, M.D.; Lawrence Chang, M.D., M.P.H.; John M. Magenau, M.D.; Attaphol Pawarode; Carrie Kitko, M.D.; Sophie Paczesny, M.D., Ph.D.; Edward M. Peres, M.D.; Gregory A. Yanik, M.D.; Michael Lehmann, M.D.; and James L.M. Ferrara, M.D., D.Sc. From Washington University, St. Louis: John F. DiPersio, M.D., Ph.D., and Keith Stockerl-Goldstein, M.D. From Mie University Hospital, Japan: Isao Tawara, M.D., Ph.D. From Sutter East Bay Medical Foundation, Berkeley, Calif.: Oleg I. Krijanovski, Ph.D., M.D. From University of Alabama, Birmingham: Shin Mineishi, M.D. From University of Colorado Health Science Center: Charles A. Dinarello, M.D.
Funding: National Institutes of Allergy and Infectious Diseases grant A1091623-01, National Cancer Institute grant CA143379, Leukemia and Lymphoma Society, St. Baldrick's Foundation.
Reference: 54th Annual Meeting of the American Society of Hematology, Atlanta, Dec. 8-11, 2012. Abstract No. 740, Targeting Histone Deacetylases as a New Strategy for Graft Versus Host Disease Prevention.
U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, www.mcancer.org
Clinical trials at U-M, www.UMClinicalStudies.org/cancer
More articles from Health and Medicine:
Primary care: strengthening the health system's first port of call
17.05.2013 | European Health Forum Gastein
Study Finds Plasmin—Delivered Through A Bubble—More Effective Than Tpa In Busting Clots
16.05.2013 | University of Cincinnati Academic Health Center
Researchers have shown that, by using global positioning systems (GPS) to measure ground deformation caused by a large underwater earthquake, they can provide accurate warning of the resulting tsunami in just a few minutes after the earthquake onset.
For the devastating Japan 2011 event, the team reveals that the analysis of the GPS data and issue of a detailed tsunami alert would have taken no more than three minutes. The results are published on 17 May in Natural Hazards and Earth System Sciences, an open access journal of ...
A new study of glaciers worldwide using observations from two NASA satellites has helped resolve differences in estimates of how fast glaciers are disappearing and contributing to sea level rise.
The new research found glaciers outside of the Greenland and Antarctic ice sheets, repositories of 1 percent of all land ice, lost an average of 571 trillion pounds (259 trillion kilograms) of mass every year during the six-year study period, making the oceans rise 0.03 inches (0.7 mm) per year. ...
About 99% of the world’s land ice is stored in the huge ice sheets of Antarctica and Greenland, while only 1% is contained in glaciers.
However, the meltwater of glaciers contributed almost as much to the rise in sea level in the period 2003 to 2009 as the two ice sheets: about one third. This is one of the results of an international study with the involvement of geographers from the University of Zurich.
Second sound is a quantum mechanical phenomenon, which has been observed only in superfluid helium.
Physicists from the University of Innsbruck, Austria, in collaboration with colleagues from the University of Trento, Italy, have now proven the propagation of such a temperature wave in a quantum gas. The scientists have published their historic findings in the journal Nature.
Below a critical temperature, certain fluids become superfluid ...
Researchers use synthetic silicate to stimulate stem cells into bone cells
In new research published online May 13, 2013 in Advanced Materials, researchers from Brigham and Women's Hospital (BWH) are the first to report that synthetic silicate nanoplatelets (also known as layered clay) can induce stem cells to become bone cells without the need of additional bone-inducing factors.
Synthetic silicates are made ...
17.05.2013 | Physics and Astronomy
17.05.2013 | Physics and Astronomy
17.05.2013 | Physics and Astronomy
17.05.2013 | Event News
15.05.2013 | Event News
08.05.2013 | Event News